INDICATORS ON LINSITINIB FDA APPROVAL YOU SHOULD KNOW

Linsitinib is a small-molecule inhibitor of IGF-1R, taken 2 times each day. From the stage 2b/3 LIDS trial, much more patients treated using a 150mg dose with the drug realized a 2mm or superior reduction in proptosis soon after 24 months when compared to placebo, which was a statistically significant difference.Despite the fact that the combinatio